JP2017537622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537622A5 JP2017537622A5 JP2017529284A JP2017529284A JP2017537622A5 JP 2017537622 A5 JP2017537622 A5 JP 2017537622A5 JP 2017529284 A JP2017529284 A JP 2017529284A JP 2017529284 A JP2017529284 A JP 2017529284A JP 2017537622 A5 JP2017537622 A5 JP 2017537622A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- acid sequence
- domain
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 51
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 34
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 239000013598 vector Substances 0.000 claims 10
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 claims 9
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 claims 9
- 230000011664 signaling Effects 0.000 claims 9
- 102000003816 Interleukin-13 Human genes 0.000 claims 8
- 108090000176 Interleukin-13 Proteins 0.000 claims 8
- 210000004962 mammalian cell Anatomy 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 230000001086 cytosolic effect Effects 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 239000013603 viral vector Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 108010016626 Dipeptides Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 102200146131 rs1131692037 Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086346P | 2014-12-02 | 2014-12-02 | |
| US62/086,346 | 2014-12-02 | ||
| PCT/US2015/063267 WO2016089916A1 (en) | 2014-12-02 | 2015-12-01 | Methods and compositons for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537622A JP2017537622A (ja) | 2017-12-21 |
| JP2017537622A5 true JP2017537622A5 (OSRAM) | 2019-01-10 |
Family
ID=56078487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529284A Pending JP2017537622A (ja) | 2014-12-02 | 2015-12-01 | がんを治療するための方法及び組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9650428B2 (OSRAM) |
| EP (1) | EP3227317A4 (OSRAM) |
| JP (1) | JP2017537622A (OSRAM) |
| KR (1) | KR20180041087A (OSRAM) |
| CN (1) | CN107709353A (OSRAM) |
| AR (1) | AR102879A1 (OSRAM) |
| AU (1) | AU2015355084A1 (OSRAM) |
| BR (1) | BR112017011771A2 (OSRAM) |
| CA (1) | CA2969714A1 (OSRAM) |
| EA (1) | EA201791210A1 (OSRAM) |
| HK (1) | HK1251862A1 (OSRAM) |
| IL (1) | IL252610A0 (OSRAM) |
| MX (1) | MX2017007272A (OSRAM) |
| PH (1) | PH12017501031A1 (OSRAM) |
| SG (2) | SG11201704519YA (OSRAM) |
| TW (1) | TW201636425A (OSRAM) |
| UY (1) | UY36418A (OSRAM) |
| WO (1) | WO2016089916A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9512194B2 (en) | 2012-01-27 | 2016-12-06 | The Board Of Trustees Of The Leland Stanford Junior University | Modified IL-13 polypeptides |
| JP6445434B2 (ja) | 2012-08-09 | 2018-12-26 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | スーパーカインおよびシンセカイン：新規かつ増強されたシグナル伝達活性を有する再利用されるサイトカイン |
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| BR112017011771A2 (pt) | 2014-12-02 | 2018-07-10 | Prospect Chartercare Rwmc Llc | métodos e composições para o tratamento de câncer |
| PT3310805T (pt) * | 2015-06-19 | 2021-05-19 | Kobold Sebastian | Proteínas de fusão pd-1-cd28 e a sua utilização em medicina |
| ES2877090T3 (es) * | 2015-08-05 | 2021-11-16 | Cellabmed Inc | Receptor de antígenos quiméricos y células T en las que se expresa el receptor de antígenos quiméricos |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| WO2018112266A1 (en) * | 2016-12-14 | 2018-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13 superkine: immune cell targeting constructs and methods of use thereof |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| CN110753555A (zh) | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | 表达工程化抗原受体的免疫细胞 |
| WO2019073299A1 (en) | 2017-10-10 | 2019-04-18 | Medicenna Therapeutics, Inc. | IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS |
| WO2019100079A1 (en) * | 2017-11-20 | 2019-05-23 | Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center | Compositions for improving car-t cell functionality and user thereof |
| KR20250010750A (ko) * | 2017-12-20 | 2025-01-21 | 포세이다 테라퓨틱스, 인크. | Vcar 조성물 및 사용 방법 |
| AU2019209432A1 (en) | 2018-01-22 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| US11701405B2 (en) * | 2018-01-26 | 2023-07-18 | City Of Hope | Chimeric antigen receptors and methods for reducing toxicity |
| CN111936518A (zh) | 2018-02-06 | 2020-11-13 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car |
| CN110157674A (zh) * | 2018-02-12 | 2019-08-23 | 深圳宾德生物技术有限公司 | 一种靶向性t淋巴细胞及其制备方法和应用 |
| CN110144326A (zh) * | 2018-02-12 | 2019-08-20 | 深圳宾德生物技术有限公司 | 一种靶向性抗肿瘤t细胞及其制备方法和应用 |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| CN108440674A (zh) * | 2018-04-28 | 2018-08-24 | 杭州荣泽生物科技有限公司 | 一种Trop-2特异性嵌合抗原受体细胞制备及其用途 |
| US12404497B2 (en) | 2018-06-01 | 2025-09-02 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof |
| JP2023512250A (ja) * | 2020-01-31 | 2023-03-24 | シティ・オブ・ホープ | ＩＬ１３Ｒα２陽性悪性腫瘍の治療のための標的キメラ抗原受容体修飾Ｔ細胞 |
| WO2021241719A1 (ja) * | 2020-05-28 | 2021-12-02 | 中外製薬株式会社 | 改良されたグランザイムｂ改変体 |
| CA3193009A1 (en) * | 2020-08-26 | 2022-03-03 | The Regents Of The University Of California | Methods and compositions for treating glioblastoma |
| WO2022056398A1 (en) * | 2020-09-11 | 2022-03-17 | University Of Georgia Research Foundation, Inc. | Compositions and methods of use thereof for prevention and treatment of influenza infections |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN114907485B (zh) * | 2021-02-08 | 2024-04-26 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| CN113304267B (zh) * | 2021-06-11 | 2022-03-15 | 河南大学 | 肺癌的治疗靶点及其应用 |
| CN114014941B (zh) * | 2022-01-10 | 2022-04-12 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的嵌合抗原受体及其用途 |
| CN116549667B (zh) * | 2023-05-29 | 2024-02-09 | 四川普锐特药业有限公司 | 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965126A (en) * | 1996-03-25 | 1999-10-12 | The Penn State Research Foundation | use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents |
| EP1222289B1 (en) * | 1999-10-20 | 2008-04-16 | The Johns Hopkins University School Of Medicine | Chimeric immunogenic compositions and nucleic acids encoding them |
| IL163515A0 (en) * | 2002-03-01 | 2005-12-18 | Bristol Myers Squibb Co | Transgenic non-human mammals |
| AU2003223497A1 (en) * | 2002-04-05 | 2003-10-27 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
| US7709625B2 (en) * | 2004-06-10 | 2010-05-04 | The Board Of Regents Of The University Of Texas | Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy |
| WO2007075077A1 (es) * | 2005-11-16 | 2007-07-05 | Universidad Nacional Autonoma De Mexico | Uso de agentes modificantes del transcriptoma más quimioterapia o radioterapia contra el cáncer |
| CN101438158A (zh) * | 2006-03-06 | 2009-05-20 | 阿穆尼克斯股份有限公司 | 遗传包和其应用 |
| US20080206139A1 (en) * | 2006-11-03 | 2008-08-28 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
| PL3006459T3 (pl) * | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| ES2621874T3 (es) * | 2010-03-26 | 2017-07-05 | Memorial Sloan-Kettering Cancer Center | Anticuerpos para MUC16 y métodos de uso de los mismos |
| WO2014090985A1 (en) * | 2012-12-13 | 2014-06-19 | Universität Leipzig | T-cell modulation by exon skipping |
| LT2956175T (lt) * | 2013-02-15 | 2017-12-11 | The Regents Of The University Of California | Chimerinis antigeno receptorius ir jo panaudojimo būdai |
| EP2968601A1 (en) * | 2013-03-10 | 2016-01-20 | Baylor College Of Medicine | Chemotherapy-resistant immune cells |
| ES2792849T3 (es) | 2014-02-10 | 2020-11-12 | Univ Emory | Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer |
| BR112017011771A2 (pt) | 2014-12-02 | 2018-07-10 | Prospect Chartercare Rwmc Llc | métodos e composições para o tratamento de câncer |
-
2015
- 2015-12-01 BR BR112017011771A patent/BR112017011771A2/pt not_active Application Discontinuation
- 2015-12-01 SG SG11201704519YA patent/SG11201704519YA/en unknown
- 2015-12-01 KR KR1020177018139A patent/KR20180041087A/ko not_active Withdrawn
- 2015-12-01 SG SG10202103475XA patent/SG10202103475XA/en unknown
- 2015-12-01 HK HK18110565.4A patent/HK1251862A1/zh unknown
- 2015-12-01 WO PCT/US2015/063267 patent/WO2016089916A1/en not_active Ceased
- 2015-12-01 EP EP15865800.5A patent/EP3227317A4/en not_active Withdrawn
- 2015-12-01 CA CA2969714A patent/CA2969714A1/en not_active Abandoned
- 2015-12-01 JP JP2017529284A patent/JP2017537622A/ja active Pending
- 2015-12-01 AU AU2015355084A patent/AU2015355084A1/en not_active Abandoned
- 2015-12-01 US US14/956,299 patent/US9650428B2/en not_active Expired - Fee Related
- 2015-12-01 CN CN201580074883.3A patent/CN107709353A/zh active Pending
- 2015-12-01 MX MX2017007272A patent/MX2017007272A/es unknown
- 2015-12-01 EA EA201791210A patent/EA201791210A1/ru unknown
- 2015-12-02 AR ARP150103939A patent/AR102879A1/es unknown
- 2015-12-02 UY UY0001036418A patent/UY36418A/es not_active Application Discontinuation
- 2015-12-02 TW TW104140317A patent/TW201636425A/zh unknown
-
2017
- 2017-05-09 US US15/590,961 patent/US20180072789A1/en not_active Abandoned
- 2017-06-01 IL IL252610A patent/IL252610A0/en unknown
- 2017-06-02 PH PH12017501031A patent/PH12017501031A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537622A5 (OSRAM) | ||
| Heidbuechel et al. | Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies | |
| JP2022109953A5 (OSRAM) | ||
| JP2022066290A (ja) | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 | |
| JP2018529380A5 (OSRAM) | ||
| JP6919091B2 (ja) | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 | |
| JP2023139070A5 (OSRAM) | ||
| CN103483452B (zh) | 双信号独立的嵌合抗原受体及其用途 | |
| JP2017537627A5 (OSRAM) | ||
| JP2018516092A5 (OSRAM) | ||
| JP2020529841A5 (OSRAM) | ||
| JP2019535262A5 (OSRAM) | ||
| JP2017538401A5 (OSRAM) | ||
| JP2019150066A5 (OSRAM) | ||
| CN111886243A (zh) | 非-hla限制性t细胞受体及其用途 | |
| HRP20190472T1 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| JP2018518459A5 (OSRAM) | ||
| JP2017500869A5 (OSRAM) | ||
| JP2018513687A5 (OSRAM) | ||
| JP2017526361A5 (OSRAM) | ||
| JP2016519068A5 (OSRAM) | ||
| JP2017529067A5 (OSRAM) | ||
| JP2018505139A5 (OSRAM) | ||
| JP2020513754A5 (OSRAM) | ||
| CN108137670A (zh) | Ny-eso-1特异性tcr及其使用方法 |